Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.

Date publication

mai 2019

Journal

Gut

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BEN ABDELGHANI Meher , Dr BOREL Christian , Pr BOUCHE Olivier , Pr GHIRINGHELLI François , Pr HOEFFEL Christine , Dr JOUVE Jean-Louis , Pr LEPAGE Côme

Tous les auteurs :
Dohan A, Gallix B, Guiu B, Le Malicot K, Reinhold C, Soyer P, Bennouna J, Ghiringhelli F, Barbier E, Boige V, Taieb J, Bouché O, François E, Phelip JM, Borel C, Faroux R, Seitz JF, Jacquot S, Ben Abdelghani M, Khemissa-Akouz F, Genet D, Jouve JL, Rinaldi Y, Desseigne F, Texereau P, Suc E, Lepage C, Aparico T, Hoeffel C,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31101691

Résumé

The objective of this study was to build and validate a radiomic signature to predict early a poor outcome using baseline and 2-month evaluation CT and to compare it to the RECIST1·1 and morphological criteria defined by changes in homogeneity and borders.

Mots clés

chemotherapy, clinical decision making, colorectal cancer, colorectal metastases, computerised image analysis

Référence

Gut. 2019 May 17;: